Quantity
Price
$46.00
Total Price: $0.00
Contact Information
Recombinant Human Apolipoprotein A-I/ApoAI Protein (His Tag, E. coli)
SKU: PKSH032081-50
Recombinant Human Apolipoprotein A-I/ApoAI Protein (His Tag, E. coli)
| SKU # | PKSH032081 |
| Expression Host | E.coli |
Description
| Synonyms | APOA1, Apo-AI, ApoA-I, Apolipoprotein A-I, Apolipoprotein A1 |
| Species | Human |
| Expression Host | E.coli |
| Sequence | Arg19-Gln267 |
| Accession | P02647 |
| Calculated Molecular Weight | 30.2 kDa |
| Observed Molecular Weight | 28 kDa |
| Tag | C-His |
| Bio-activity | Not validated for activity |
Properties
| Purity | > 95 % as determined by reducing SDS-PAGE. |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method. |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 6% Sucrose, 4% Mannitol, 50mM Nacl, 0.05% Tween 80, pH7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual. |
| Reconstitution | Please refer to the printed manual for detailed information. |
Background
Apolipoprotein A1 (APOA1) is a secreted protein which belongs to the Apolipoprotein A1/A4/E family. APOA1 is the major protein component of high density lipoprotein (HDL) in plasma. APOA1 plays a critical role in various biological processes; such as Cholesterol metabolism; Lipid metabolism and transport; Steroid metabolism. APOA1 promotes cholesterol efflux from tissues to the liver and thus helps to clear cholesterol from arteries. Defects in this gene resulted in HDL deficiencies; including Tangier disease (TGD); systemic non-neuropathic amyloidosis; premature coronary artery disease; hepatosplenomegaly and progressive muscle wasting and weakness. In addition; ApoA-I is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.